Cytek Biosciences stock fell 11.66 percent on October 6

Published on 10/07/2026 at 02:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cytek Biosciences stock reached USD 6.21 before the October 6 selloff. Q2 revenue rose 6 percent to USD 48.14 million, while analysts kept a Hold consensus.

CTKB, US23285D1090, Illustration mit AI erstellt.

Cytek Biosciences stock (ISIN US23285D1090) fell 11.66 percent and was last at USD 5.38 on Nasdaq on October 6, 2026 at 4:00 p.m. ET. The move followed an intraday high of USD 6.21, while the company remains defined by growing revenue and continuing losses.

Price retreats from yearly high

Cytek's market capitalization stood at USD 694.8 million and trading volume reached 2,051,758 shares on October 6, 2026. The 52-week low was USD 3.31 and the 52-week high was USD 6.21, placing the latest price USD 0.83 below the yearly peak.

MarketBeat reported on October 6, 2026 that Cytek reached USD 6.21 during the session and had previously closed at USD 6.09. The contrast between the intraday peak and the later USD 5.38 quote shows how quickly the session's gains reversed.

Revenue grows while losses widen

For the second quarter ended June 30, 2026, revenue rose 6 percent year over year to USD 48.14 million, according to The Globe and Mail. The same quarter produced a GAAP net loss of USD 12.2 million, compared with a USD 5.6 million loss in the prior-year quarter.

Recurring revenue offered a more constructive operating signal: reagent and service revenue reached USD 18.5 million, up 8 percent year over year, and represented 35 percent of trailing twelve-month revenue versus 32 percent a year earlier. Service revenue alone rose 10 percent to USD 15.6 million.

Cytek also raised the low end of its full-year 2026 revenue guidance to USD 207 million to USD 212 million, lifting the midpoint by USD 1 million. The guidance gives investors a quantified benchmark for the second half, but the quarterly loss shows that revenue growth has not yet translated into GAAP profitability.

Analysts hold a cautious view

MarketBeat reported a Hold consensus from six analysts on October 6, 2026, with three Buy ratings, two Hold ratings and one Sell rating. The average price target was USD 5.56, which places the target 3.35 percent above the USD 5.38 reference price.

The analyst split reflects the central tension in the latest figures. Cytek's United States revenue rose 18 percent in Q2 2026, while EMEA revenue fell 8 percent, according to The Globe and Mail. That regional gap makes execution in the United States and China important as the company expands its instrument, service and reagent base.

Cytek stock stays below its high

Cytek Biosciences stock was last at USD 5.38 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, with the USD 6.21 52-week high providing the clearest near-term chart reference.